Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.
Scientists have developed a way to grow self-organising bovine tissues from cultured embryonic stem cells to recreate animal muscle fibres in cultivated meat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results